InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity

InMed Pharmaceuticals Inc.

Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.
Long-term study in 5xFAD mouse model with advanced disease; treatment duration longer than previous studies.
INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in dose-dependent manner.
Immunohistochemistry showed dose-dependent reduction in amyloid-beta immunoreactivity and partial restoration of MAP2.
Behavioral improvements: cognitive function, anxiety-related behavior, sensory responsiveness restored or approaching normal.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.